Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen Inc. possesses a positive outlook due to its innovative pipeline focused on unmet medical needs in retinal diseases, particularly through the development of the OCU400 modifier gene therapy, which has demonstrated strong efficacy and safety in phase I/II studies. The company's collaboration agreements and potential for mergers and acquisitions add to its financial attractiveness and strategic growth opportunities. Additionally, past data releases indicate a consistent benefit in treated patients, further supporting Ocugen's commitment to improving patient health outcomes.

Bears say

Ocugen Inc. is facing a negative outlook due to disappointing clinical trial results and challenges in securing funding, which is indicative of broader market concerns. The latest data shows only a 20.2% slowing of geographic atrophy (GA) lesion growth in treated eyes compared to untreated eyes, suggesting limited efficacy of its treatments. Additionally, the company cites "poor market conditions" and compliance issues with Nasdaq as significant barriers to obtaining necessary investment, further emphasizing its precarious financial position.

Ocugen, Inc. (OCGN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.